Dear Madam, Dear Sir, Dear Investor,
It is with great pleasure that I welcome you to the website dedicated to investors.
Ikonisys' innovative approach is the automated detection, analysis and interpretation of rare and very rare cells. Ikonisys deploys a combination of equipment, software and reagents for automated diagnosis to improve the reporting of test results from medical laboratories.
Ikonisys' ambition is the early and accurate detection of cancerous diseases.
We thank you for your interest in our company,
Ikonisys and Negma Group announce the end of their financing agreement
Ikonisys announces its participation in the Investor Access forum
Ikonisys announces the initation of coverage of its stock by Sphene Capital
Succes of Ikonisys' initial public offering on Euronext Growth® Paris
Subscribe to email alert
Ask us your questions